Purpose: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material is often an effusion and biochemical analysis of soluble markers may provide additional diagnostic information. This study aimed to establish a predictive model using biomarkers from pleural effusions, to allow early and accurate diagnosis. Patients and Methods: Effusions were collected prospectively from 190 consecutive patients at a regional referral centre. Hyaluronan, N-ERC/mesothelin, C-ERC/mesothelin, osteopontin, syndecan-1, syndecan-2, and thioredoxin were measured using ELISA and HPLC. A predictive model was generated and validated using a second prospective set of 375 effusions collected consecutively at a different referral centre...
Malignant pleural mesothelioma (MM) is a highly aggressive tumor characterized by a poor prognosis. ...
Malignant mesothelioma (MM) is a pleural malignant tumor that results predominantly from exposure to...
The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being in...
PURPOSE: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material...
Purpose: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material...
Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material is often...
Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers....
International audienceWe assessed comparatively the diagnostic value of two potential malignant pleu...
AbstractBackgroundMalignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor surviv...
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer with a median survival of 12month...
Background: Malignant pleural mesothelioma (MPM) is a rapidly fatal tumor of increasing worldwide in...
Rationale. The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficul...
<p>Levels of hyaluronan, N-ERC/mesothelin, C-ERC/mesothelin, osteopontin, syndecan-2, syndecan-1, an...
RATIONALE: Serum mesothelin is a new biomarker for the diagnosis of mesothelioma. Patients with meso...
In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, solub...
Malignant pleural mesothelioma (MM) is a highly aggressive tumor characterized by a poor prognosis. ...
Malignant mesothelioma (MM) is a pleural malignant tumor that results predominantly from exposure to...
The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being in...
PURPOSE: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material...
Purpose: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material...
Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material is often...
Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers....
International audienceWe assessed comparatively the diagnostic value of two potential malignant pleu...
AbstractBackgroundMalignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor surviv...
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer with a median survival of 12month...
Background: Malignant pleural mesothelioma (MPM) is a rapidly fatal tumor of increasing worldwide in...
Rationale. The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficul...
<p>Levels of hyaluronan, N-ERC/mesothelin, C-ERC/mesothelin, osteopontin, syndecan-2, syndecan-1, an...
RATIONALE: Serum mesothelin is a new biomarker for the diagnosis of mesothelioma. Patients with meso...
In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, solub...
Malignant pleural mesothelioma (MM) is a highly aggressive tumor characterized by a poor prognosis. ...
Malignant mesothelioma (MM) is a pleural malignant tumor that results predominantly from exposure to...
The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being in...